Curcumin: A natural substance with potential efficacy in Alzheimer's disease

Journal of Experimental Pharmacology

Volumn 5, Issue , 2013, Pages 23-31

  Potter, Pamela E ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Curcumin; Neuroprotection; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; BIOPERINE; BLACK PEPPER EXTRACT; CURCUMIN; DONEPEZIL; GALANTAMINE; LONGVIDA; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; CANCER PREVENTION; CLINICAL TRIAL (TOPIC); COGNITION; DISEASE COURSE; DRUG BIOAVAILABILITY; ENCEPHALITIS; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK;

EID: 85015468275     PISSN: None     EISSN: 11791454     Source Type: Journal    
DOI: 10.2147/JEP.S26803     Document Type: Article

References (166)

1. Price DL, Sisodia SS, Gandy SE. Amyloid β amyloidosis in Alzheimer's disease. Curr Opin Neurol. 1995;8(4):268-274.
2. Hebert LE, Wilson RS, Gilley DW, et al. Decline of language among women and men with Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci. 2000;55(6):P354-P360. (Pubitemid 32010262)
3. www.alz.org [homepage on the Internet]. Alzheimer's Disease Facts and Figures. Available from: http://www.alz.org/alzheimers-disease-facts-and- figures.asp. Accessed April 8, 2013.
4. Palmer AM. Neurochemical studies of Alzheimer's disease. Neurodegeneration. 1996;5(4):381-391. (Pubitemid 27077898)
5. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-414.
6. Hunt CE, Turner AJ. Cell biology, regulation and inhibition of β-secretase (BACE-1). FEBS J. 2009;276(7):1845-1859.
7. Lichtenthaler SF. α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J Neurochem. 2011;116(1): 10-21.
8. Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiology. J Biol Chem. 2008;283(44):29621-29625.
9. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17(5):1005-1013. (Pubitemid 26424026)
10. Wolfe MS. The γ-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006;45(26):7931-7939. (Pubitemid 43993216)
11. Twomey C, McCarthy JV. Presenilin-1 is an unprimed glycogen synthase kinase-3β substrate. FEBS Lett. 2006;580(17):4015-4020. (Pubitemid 44037562)
12. DaRocha-Souto B, Coma M, Perez-Nievas BG, et al. Activation of glycogen synthase kinase-3β mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis. 2012;45(1):425-437.
13. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol. 1997;56(1):70-78. (Pubitemid 127470328)
14. Toda T, Noda Y, Ito G, Maeda M, Shimizu T. Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer's disease. J Biomed Biotechnol. 2011;2011:617974.
15. Sawamura N, Morishima-Kawashima M, Waki H, et al. Mutant presenilin 2 transgenic mice. A large increase in the levels of Aβ 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. J Biol Chem. 2000;275(36):27901- 27908.
16. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99-102. (Pubitemid 26332733)
17. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22(5):1858-1867. (Pubitemid 35386304)
18. Gordon MN, King DL, Diamond DM, et al. Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001;22(3):377-385. (Pubitemid 32510908)
19. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-356. (Pubitemid 34790756)
20. Goate A, Hardy J. Twenty years of Alzheimer's disease-causing mutations. J Neurochem. 2012;120(Suppl 1):3-8.
21. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PloS One. 2012;7(2):e31039.
22. Sisodia SS, Price DL. Role of the β-amyloid protein in Alzheimer's disease. FASEB J. 1995;9(5):366-370.
23. Roher AE, Esh CL, Kokjohn TA, et al. Amyloid β peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009;5(1):18-29.
24. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38(11):1688-1693. (Pubitemid 18265030)
25. Kar S, Quirion R. Amyloid β peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. Prog Brain Res. 2004;145:261-274. (Pubitemid 37442949)
26. Kurt MA, Davies DC, Kidd M. Paired helical filament morphology varies with intracellular location in Alzheimer's disease brain. Neurosci Lett. 1997;239(1):41-44. (Pubitemid 28055845)
27. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007; 8(9):663-672. (Pubitemid 47283144)
28. Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis. 2006;9(Suppl 3): 195-207. (Pubitemid 44253313)
29. Alberdi E, Sanchez-Gomez MV, Cavaliere F, et al. Amyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47(3):264-272.
30. Kuner P, Schubenel R, Hertel C. β-amyloid binds to p57NTR and activates NFκB in human neuroblastoma cells. J Neurosci Res. 1998;54(6):798-804. (Pubitemid 28544380)
31. Strosznajder JB, Zambrzycka A, Kacprzak MD, Strosznajder RP. Amyloid β peptide 25-35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. J Mol Neurosci. 1999;12(2):101-109. (Pubitemid 29473323)
32. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res. 2010;33(10):1539-1556.
33. Cai Z, Zhao B, Ratka A. Oxidative stress and β-amyloid protein in Alzheimer's disease. Neuromolecular Med. 2011;13(4):223-250.
34. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21(3):383-421. (Pubitemid 30349107)
35. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998;33(5):371-378. (Pubitemid 28354931)
36. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8): 759-767. (Pubitemid 32678256)
37. Butterfield DA, Boyd-Kimball D. Amyloid β-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 2004;14(4):426-432. (Pubitemid 39524972)
38. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 2000;71(2):621S-629S. (Pubitemid 30061247)
39. Yao Y, Chinnici C, Tang H, Trojanowski JQ, Lee VM, Pratico D. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation. 2004; 1(1):21.
40. Simpson JE, Ince PG, Haynes LJ, et al. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Neuropathol Appl Neurobiol. 2010;36(1):25-40.
41. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des. 2010;16(25):2766-2778.
42. Bregman N, Karni A, Korczyn AD. Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia? Arch Neurol. 2009;66(4):539-540.
43. McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer's disease - a mini-review. Gerontology. 2010;56(1):3-14.
44. Cahill CM, Lahiri DK, Huang X, Rogers JT. Amyloid precursor protein and α synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta. 2009;1790(7): 615-628.
45. Cho HH, Cahill CM, Vanderburg CR, et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem. 2010;285(41):31217-31232.
46. Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics. 2008;5(3):433-442. (Pubitemid 351952486)
47. Osborn GG, Saunders AV. Current treatments for patients with Alzheimer disease. J Am Osteopath Assoc. 2010;110(9 Suppl 8): S16-S26.
48. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-221.
49. Birks J. Cholinesterase inhibitors for Alzheimer's disease [review]. Cochrane Database Syst Rev. 2006;1:CD005593.
50. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211-225. (Pubitemid 352037861)
51. Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem. 2012;120(Suppl 1):22-33.
52. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12(5):787-800.
53. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia [review]. Cochrane Database Syst Rev. 2006;2:CD003154.
54. Molinuevo JL, Garcia-Gil V, Villar A. Memantine: an antiglutamatergic option for dementia. Am J Alzheimers Dis Other Demen. 2004;19(1): 10-18. (Pubitemid 38200503)
55. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists. Brain Res. 2001;905(1-2):220-223. (Pubitemid 32553856)
56. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from β-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis. 2004;17(2):337-348. (Pubitemid 39345789)
57. Bordji K, Becerril-Ortega J, Nicole O, Buisson A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J Neurosci. 2010;30(47):15927-15942.
58. Bordji K, Becerril-Ortega J, Buisson A. Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. Rev Neurosci. 2011;22(3):285-294.
59. Golde TE. Disease modifying therapy for AD? J Neurochem. 2006; 99(3):689-707. (Pubitemid 44583429)
60. Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem. 2008;15(24): 2433-2455.
61. Beusterien KM, Thomas SK, Gause D, Kimel M, Arcona S, Mirski D. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs. 2004;18(15):1143-1148. (Pubitemid 40007496)
62. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni Jr. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51(7):937-944. (Pubitemid 36871141)
63. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425-432. (Pubitemid 26324038)
64. Sastre M, Gentleman SM. NSAIDs: how they work and their prospects as therapeutics in Alzheimer's disease. Front Aging Neurosci. 2010;2:20.
65. Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR. NO-flurbiprofen reduces amyloid-β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J Neurochem. 2009;111(3): 766-776.
66. Lee RK, Wurtman RJ. Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Ann N Y Acad Sci. 2000;920:261-268. (Pubitemid 32056580)
67. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9(5):661-679.
68. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43(8):1609-1611. (Pubitemid 23230557)
69. Intveld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515- 1521. (Pubitemid 33144916)
70. Martin BK, Szekely C, Brandt J, et al ADAPT Research Group. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7): 896-905. (Pubitemid 352008472)
71. Meinert CL, McCaffrey LD, Breitner JC. ADAPT Research Group. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement. 2009;5(2):93-104.
72. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology. 2007;69(3):275-282. (Pubitemid 47205690)
73. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327(7407):128.
74. Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001;57(6):985-989. (Pubitemid 32880190)
75. Shaji S, Bose S, Verghese A. Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry. 2005;186:136-140. (Pubitemid 40193783)
76. Vas CJ, Pinto C, Panikker D, et al. Prevalence of dementia in an urban Indian population. Int Psychogeriatr. 2001;13(4):439-450. (Pubitemid 34326972)
77. Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1-17.
78. Ganguli M, Chandra V, Kamboh MI, et al. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US cross-national dementia study. Arch Neurol. 2000;57(6):824-830. (Pubitemid 30397184)
79. Altamura C, Squitti R, Pasqualetti P, et al. What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia? Eur J Neurol. 2007;14(6):679-682. (Pubitemid 46849043)
80. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673-680. (Pubitemid 29266465)
81. Ahn Jo S, Ahn K, Kim JH, et al. ApoE-ε 4-dependent association of the choline acetyltransferase gene polymorphisms (2384G. A and 1882G. A) with Alzheimer's disease. Clin Chim Acta. 2006;368(1-2): 179-182. (Pubitemid 43776017)
82. Kandimalla RJ, S P, Bk B, et al. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients. Neurosci Lett. 2011;487(2):134-138.
83. Subramanian S, Sandhyarani B, Shree AND, et al. Lower levels of cerebrospinal fluid amyloid β (Aβ) in non-demented Indian controls. Neurosci Lett. 2006;407(2):121-123. (Pubitemid 44397235)
84. Commandeur JN, Vermeulen NP. Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica. 1996;26(7):667-680. (Pubitemid 26233021)
85. Joe B, Lokesh BR. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta. 1994;1224(2):255-263.
86. Reddy AC, Lokesh BR. Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem. 1992;111(1-2):117-124.
87. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105-125.
88. Rao TS, Basu N, Siddiqui HH. Anti-inflammatory activity of curcumin analogues. Indian J Med Res. 1982;75:574-578. (Pubitemid 13226183)
89. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85-94.
90. Frautschy SA, Cole GM. Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol. 2010;41(2-3):392-409.
91. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 2005;2(2):131-136. (Pubitemid 40862872)
92. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86-92. (Pubitemid 9016316)
93. Lao CD, Ruffin MT 4th, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
94. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787-809.
95. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-818.
96. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7(7):1894-1900. (Pubitemid 32994823)
97. Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Invest Drugs. 2012;21(8):1123-1140.
98. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharm Physiol. 2012;39(3):283-299.
99. Schraufstatter E, Bernt H. Antibacterial action of curcumin and related compounds. Nature. 1949;164(4167):456.
100. Dovigo LN, Pavarina AC, Carmello JC, Machado AL, Brunetti IL, Bagnato VS. Susceptibility of clinical isolates of Candida to photodynamic effects of curcumin. Lasers Surg Med. 2011;43(9): 927-934.
101. Neelofar K, Shreaz S, Rimple B, Muralidhar S, Nikhat M, Khan LA. Curcumin as a promising anticandidal of clinical interest. Can J Microbiol. 2011;57(3):204-210.
102. Zandi K, Ramedani E, Mohammadi K, et al. Evaluation of antiviral activities of curcumin derivatives against HSV-1 in Vero cell line. Nat Prod Commun. 2010;5(12):1935-1938.
103. Kolodziejczyk J, Olas B, Saluk-Juszczak J, Wachowicz B. Antioxidative properties of curcumin in the protection of blood platelets against oxidative stress in vitro. Platelets. 2011;22(4): 270-276.
104. Sandur SK, Ichikawa H, Pandey MK, et al. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med. 2007;43(4):568-580. (Pubitemid 47058232)
105. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28(8): 1765-1773. (Pubitemid 47289040)
106. Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? Trends Mol Med. 2012;18(3):138-144.
107. Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1-42) insult. Neurosci Lett. 2001;303(1):57-61. (Pubitemid 32285467)
108. Chhunchha B, Fatma N, Kubo E, Rai P, Singh SP, Singh DP. Curcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-κB regulation. Am J Physiol Cell Physiol. January 30, 2013. [Epub ahead of print.]
109. Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem. 2004;91(5):1199-1210. (Pubitemid 39587458)
110. Qin XY, Cheng Y, Yu LC. Potential protection of curcumin against intracellular amyloid β-induced toxicity in cultured rat prefrontal cortical neurons. Neurosci Lett. 2010;480(1):21-24.
111. Huang HC, Chang P, Dai XL, Jiang ZF. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem Res. 2012;37(7):1584-1597.
112. Zhang X, Yin WK, Shi XD, Li Y. Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. Eur J Pharm Sci. 2011;42(5):540-546.
113. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J Neurosci Res. 2004;75(6):742-750. (Pubitemid 38296087)
114. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892-5901. (Pubitemid 40280072)
115. Zhao LN, Chiu SW, Benoit J, Chew LY, Mu Y. The effect of curcumin on the stability of Aβ dimers. J Phys Chem B. 2012;116(25): 7428-7435.
116. Orlando RA, Gonzales AM, Royer RE, Deck LM, Vander Jagt DL. A chemical analog of curcumin as an improved inhibitor of amyloid Aβ oligomerization. PloS One. 2012;7(3):e31869.
117. Liu H, Li Z, Qiu D, Gu Q, Lei Q, Mao L. The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett. 2010;485(2):83-88.
118. Zhang C, Browne A, Child D, Tanzi RE. Curcumin decreases amyloid-β peptide levels by attenuating the maturation of amyloid-β precursor protein. J Biol Chem. 2010;285(37):28472-28480.
119. Zhang X, Zhang HM, Si L, Li Y. Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer's disease. Pharmacol Rep. 2011;63(5):1101-1108.
120. Jiao Y, Wilkinson J 4th, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009;113(2):462-469.
121. Dai MC, Zhong ZH, Sun YH, et al. Curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis. Neurosci Lett. 2013;536:41-46.
122. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis. 2004;6(4):367-377. (Pubitemid 39287248)
123. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21): 8370-8377. (Pubitemid 33051435)
124. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001;22(6):983-991. (Pubitemid 34066567)
125. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008;326(1): 196-208. (Pubitemid 351872144)
126. Ahmed T, Enam SA, Gilani AH. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience. 2010;169(3):1296-1306.
127. Ahmed T, Gilani AH. A comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an Aβ plus ibotenic acid-infused rat model of Alzheimer's disease. Brain Res. 2011;1400:1-18.
128. Ma QL, Yang F, Rosario ER, et al. β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009;29(28):9078-9089.
129. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28(1):110-113.
130. Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4(5):43.
131. Ringman JM, Cole GM, Teng E, et al. Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study. Alzheimers Dement. 2008;4(Suppl 4):T774.
132. www.clinicaltrials.gov [homepage on the Internet]. http://www.alz.org/ alzheimers-disease-facts-and-figures.asp Accessed April 8, 2013.
133. www.alzforum.org [homepage on the Internet]. Drugs in Clinical Trials. Available from: http://www.alzforum.org/drg/drc/detail.asp?id=137. Accessed April 8, 2013.
134. Mancuso C, Siciliano R, Barone E. Curcumin and Alzheimer disease: this marriage is not to be performed. J Biol Chem. 2011; 286(3):le3.
135. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900.
136. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356. (Pubitemid 28234275)
137. Belkacemi A, Doggui S, Dao L, Ramassamy C. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med. 2011;13:e34.
138. Chen SY, Chen Y, Li YP, et al. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease. Bioorg Med Chem. 2011;19(18): 5596-5604.
139. Bolognesi ML, Bartolini M, Tarozzi A, et al. Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg Med Chem Lett. 2011;21(9): 2655-2658.
140. Dadhaniya P, Patel C, Muchhara J, et al. Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol. 2011;49(8):1834-1842.
141. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci. 2011;359(1):318-325.
142. Manju S, Sreenivasan K. Hollow microcapsules built by layer by layer assembly for the encapsulation and sustained release of curcumin. Colloids Surf B Biointerfaces. 2011;82(2):588-593.
143. Manju S, Sreenivasan K. Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. J Pharm Sci. 2011;100(2):504-511.
144. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci. 2011;100(5): 1987-1995.
145. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm. 2010;76(3):475-485.
146. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem. 2009;57(19): 9141-9146.
147. Manju S, Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci. 2012;368(1):144-151.
148. Ghosh D, Choudhury ST, Ghosh S, et al. Nanocapsulated curcumin: oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem Biol Interact. 2012;195(3): 206-214.
149. Ghosh M, Singh AT, Xu W, Sulchek T, Gordon LI, Ryan RO. Curcumin nanodisks: formulation and characterization. Nanomedicine. 2011;7(2):162-167.
150. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3-4):223-230.
151. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351(1): 19-29.
152. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31(25):6597-6611.
153. Debnath S, Saloum D, Dolai S, et al. Dendrimer-curcumin conjugate: a water soluble and effective cytotoxic agent against breast cancer cell lines. Anticancer Agents Med Chem. January 24, 2013. [Epub ahead of print.]
154. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J. December 11, 2012. [Epub ahead of print.]
155. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11): 1118-1127.
156. Golde TE, Schneider LS, Koo EH. Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011; 69(2):203-213.
157. Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408(6815):979-982. (Pubitemid 32101644)
158. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408(6815):982-985. (Pubitemid 32101645)
159. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9(4):448-452. (Pubitemid 36460079)
160. Blennow K, Zetterberg H, Wei J, Liu E, Black R, Grundman M. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease. Alzheimers Dement. 2010;6(Suppl 4):S134-S135.
161. Laskowitz DT, Kolls BJ. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2010;74(24):2026.
162. DeMattos RB, Racke MM, Gelfanova V, et al. Identification, characterization, and comparison of amino-terminally truncated Aβ42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment. Alzheimers Dement. 2009;5(Suppl 4):P156-P157.
163. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol. 2009;66(1):48-54.
164. Eli Lilly and Company. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of Phase III clinical trials [press release]. Indianapolis, IN: Eli Lilly and Company; 2012 [August 17]. Available from: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=499794. Accessed March 8, 2013.
165. Parachikova A, Green KN, Hendrix C, LaFerla FM. Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PloS One. 2010;5(11):e14015.
166. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxid Med Cell Longev. 2012;2012:386527.